Semorinemab is under clinical development by AC Immune and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Semorinemab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Semorinemab overview
Semorinemab (RG-6100) was under development for the treatment of mild to moderate Alzheimer’s disease. The drug candidate is administered through intravenous route which acts by targeting tau protein. It is a new molecular entity. The drug candidate is a is a humanized high-affinity IgG4 isotype antibody.
AC Immune overview
AC Immune is a clinical-stage biopharmaceutical company primarily engaged in the development of precision medicine for the diagnosis, treatment, and prevention of neurodegenerative diseases. The company’s main activities involve leveraging its proprietary technology platforms, SupraAntigen and Morphomer, to develop a diverse pipeline of clinical and preclinical product candidates. These products are designed to target established and emerging neurodegenerative pathologies, with a focus on Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders. The company collaborates with industry leaders such as Takeda, Janssen, Life Molecular Imaging, and Lilly to advance its proprietary programs. The company operates globally, with a significant presence in Switzerland and the US. AC Immune is headquartered in Lausanne, Switzerland.
For a complete picture of Semorinemab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
